PDCD1 and nasopharyngeal carcinoma: Recently, two multi-center phase III studies verified the superiority of programmed cell death-1 (PD-1) inhibitor camrelizumab [3] and toripalimab [4] over the GP regimen in treating RM-NPC as the first-line treatment, respectively.